Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world upadacitinib use and treatment target achievement in moderate to severe atopic dermatitis in China (REACH-AD)
ChiCTR2400083248Phase 4Recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of upadacitinib in atopic dermatitis (AD), sponsored by Peking Union Medical College Hospital. Primary endpoints: Population characteristics at baseline and Upadacitinib utilization patterns. Started Mar 2024; status: recruiting.
02
Drugs
upadacitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on ChiCTR2400083248.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400083248.